Related Experiment Video

Updated: May 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Novel anticoagulants in atrial fibrillation stroke prevention

Nicholas B Norgard, James J Dinicolantonio, Taylor J Topping

    Therapeutic Advances in Chronic Disease
    |December 20, 2012
    PubMed

    Insights

    Novel oral anticoagulants like dabigatran, rivaroxaban, and apixaban are effective for preventing stroke in atrial fibrillation (AF) patients. These drugs offer comparable or superior efficacy and potentially better safety than warfarin.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Internal Medicine

    Background:

    • Atrial fibrillation (AF) is a common arrhythmia, with stroke being its most serious complication.
    • Warfarin is a long-established treatment for AF-related stroke prevention but has significant drawbacks.
    • Development of novel oral anticoagulants aims to improve efficacy, safety, and convenience.

    Purpose of the Study:

    • To review and compare novel oral anticoagulants (NOACs) with warfarin for thromboembolism prophylaxis in AF patients.
    • To evaluate the efficacy and safety profiles of dabigatran, rivaroxaban, and apixaban against warfarin.

    Main Methods:

    • Review of large Phase III clinical trials comparing NOACs (dabigatran, rivaroxaban, apixaban) with warfarin.
    • Analysis of data on stroke prevention and safety profiles.

    Main Results:

    • Dabigatran, rivaroxaban, and apixaban demonstrated non-inferiority to warfarin in preventing stroke.
    • Dabigatran and apixaban showed statistically superior efficacy compared to warfarin.
    • All three NOACs may offer a better safety profile than warfarin.

    Conclusions:

    • NOACs present a different pharmacologic profile, potentially reducing treatment inconveniences associated with warfarin.
    • Practitioners should consider the specific advantages and disadvantages of NOACs when managing AF patients.
    • Further clinical experience will likely clarify optimal drug selection for AF stroke prevention.

    Keywords:
    anticoagulationapixabandabigatranrivaroxabanthromboembolismwarfarin

    More Related Videos

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

    Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

    Published on: February 26, 2013

    Related Concept Videos

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...